NCT02743351 - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

December 4, 2020

Study Completion Date

November 5, 2021

Conditions

Hematologic MalignanciesAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromesChronic Myelogenous LeukemiaAcute Graft-versus-host Disease

Interventions

BIOLOGICAL

ProTmune

Ex-vivo, programmed mobilized peripheral blood (mPB) cells

BIOLOGICAL

Control Arm

Untreated mobilized peripheral blood (mPB) cells

Trial Locations (15)

23298

Virginia Commonwealth University, Richmond

37203

Sarah Cannon Research Institute, Nashville

43210

The Ohio State University, Columbus

46237

Indiana Blood and Marrow Transplant, Indianapolis

48201

Barbara Ann Karmanos Cancer Institute, Detroit

84103

Huntsman Cancer Institute (University of Utah), Salt Lake City

91010

City of Hope, Duarte

Unknown

University of Alabama, Birmingham

University of California, San Diego (UCSD) Moores Cancer Center, San Diego

University of Chicago, Chicago

Weill Cornell Medicine, New York

Jewish Hospital, Cincinnati

Oregon Health & Science University, Portland

Texas Transplant Institute, San Antonio

02215

Dana Farber Cancer Institute, Boston